[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Japan Contract Development And Manufacturing Organization Market Size, Share & Trends Analysis Report By Product (API, Drug Product), By Workflow (Clinical, Commercial), By Application, And Segment Forecasts, 2022 - 2030

October 2022 | 118 pages | ID: JC73D814CBCCEN
Grand View Research, Inc.

US$ 5,950.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
This report can be delivered to the clients within 2 Business Days

Japan Contract Development And Manufacturing Organization Market Growth & Trends

The Japan contract development and manufacturing organization market size is expected to reach USD 19.5 billion by 2030, according to a new report by Grand View Research, Inc. The market is anticipated to expand at a CAGR of 6.7% from 2022 to 2030. The main drivers of this market are rising investment by contract development and manufacturing organizations (CDMOs) for capacity expansion, a high geriatric population and growing disease burden in Japan, and low costs associated with outsourcing drug manufacturing and development services.

The COVID-19 pandemic boosted the demand for the CDMO market. Several CDMOs in Japan had tried to improve their capability by expanding their facilities even during the pandemic. For instance, in August 2020, Bushu Pharmaceuticals expanded its facility in the Misato plant in Japan to be dedicated to the storage of temperature-controlled sterile drugs and biologics. Similarly, in July 2020, CMIC Group established a new facility in Japan dedicated to processing development and GMP manufacturing of antibody drugs. Such initiatives by CDMOs in the country are expected to have a positive impact on the market.

The market players are continuously engaging in major strategic initiatives like expanding their facilities, collaborating, partnerships, new service launches, and mergers & acquisitions. For instance, in May 2020, Catalent, a market leader in clinical supply services, announced plans to buy a clinical packaging facility from Teva-Takeda Pharmaceuticals, Nagoya Aichi, Japan. By making this purchase, a new clinical GMP production and distribution hub will be created to assist clinical research. Furthermore, in July 2022, Catalent announced that it would be constructing a high-speed blister packaging line in Shiga, Japan. This will be in addition to its automated fill-and-finish production facility.

Japan Contract Development And Manufacturing Organization Market Report Highlights
  • The API product segment accounted for the largest revenue share of 80.9% in 2021. The product segment is divided into API and drug product
  • Based on application, the commercial segment dominated the market in 2021. This is due to the rising demand for generic drugs, and the high burden of chronic diseases are some factors contributing to the growth
  • The oncology segment is anticipated to register the fastest CAGR of 7.2% during the forecast period, due to the growing number of cancer cases in the country which is improving the demand for new cancer therapeutics
  • In November 2020, WuXi AppTec expanded its services offered by Cell & Gene Therapy Platform. The platform is now capable of developing, manufacturing, and introducing cell and gene therapies faster and with greater predictability
CHAPTER 1 METHODOLOGY AND SCOPE

1.1 Market Segmentation & Scope
  1.1.1 Product
  1.1.2 Workflow
  1.1.3 Application
  1.1.4 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
  1.3.1 Purchased Database
  1.3.2 Gvr’s Internal Database
  1.3.3 Secondary Sources
  1.3.4 Primary Research
  1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
  1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
  1.5.1 Approaches Used To Estimate The Market Size
    1.5.1.1 Approach 1: Parent Market Analysis
    1.5.1.2 Approach 2: Commodity Flow (Company Share Analysis)
1.6 Model Details
  1.6.1 Commodity Flow Analysis (Model 1)
  1.6.2 Volume Price Analysis (Model 2)
1.7 List Of Secondary Sources
1.8 List Of Abbreviations
1.9 Objectives
  1.9.1 Objective - 1:
  1.9.2 Objective - 2:
  1.9.3 Objective - 3:
  1.9.4 Objective - 4:

CHAPTER 2 EXECUTIVE SUMMARY

2.1 Market Outlook
2.2 Segment Outlook

CHAPTER 3 JAPAN CDMO MARKET: VARIABLES, TRENDS, & SCOPE

3.1 Market Lineage Outlook
  3.1.1 Parent market outlook
  3.1.2 Ancillary market outlook
3.2 Penetration & Growth Prospect Mapping
3.3 Market Dynamics
  3.3.1 Market Driver Analysis
    3.3.1.1 Growing demand for Biopharmaceutical drugs in Japan
    3.3.1.2 High geriatric population and growing disease burden in Japan
    3.3.1.3 Low cost associated with Outsourcing Drug Manufacturing and Development services
  3.3.2 Market Restraint Analysis
    3.3.2.1 Limited outsourcing opted for by big pharma companies
    3.3.2.2 Quality Issues While Outsourcing
3.4 Japan CDMO Market Analysis Tools
  3.4.1 Porter’s Five Forces Analysis
  3.4.2 PESTEL Analysis
3.5 Major Deals & Strategic Alliances Analysis
  3.5.1 Expansions
  3.5.2 Partnerships and Collaboration
  3.5.3 Mergers and Acquisitions
  3.5.4 Service and Product Launch
  3.5.5 Joint Venture
3.6 COVID-19 Impact

CHAPTER 4 JAPAN CDMO MARKET: PRODUCT SEGMENT ANALYSIS

4.1 Japan CDMO: Market Share Analysis, 2021 & 2030
4.2 Japan CDMO Market: Definition and Scope
4.3 API
  4.3.1 API market, 2018 - 2030 (USD Million)
  4.3.2 Type
    4.3.2.1 Traditional Active Pharmaceutical Ingredient (Traditional API)
      4.3.2.1.1 Traditional APIs market, 2018 - 2030 (USD Million)
    4.3.2.2 HP-API
      4.3.2.2.1 HP-API market, 2018 - 2030 (USD Million)
    4.3.2.3 Antibody Drug Conjugate
      4.3.2.3.1 Antibody Drug Conjugate market, 2018 - 2030 (USD Million)
    4.3.2.4 Others
      4.3.2.4.1 Others market, 2018 - 2030 (USD Million)
  4.3.3 Synthesis
    4.3.3.1 Synthetic
      4.3.3.1.1 Synthetic market, 2018 - 2030 (USD Million)
      4.3.3.1.2 Solid
      4.3.3.1.3 solid market, 2018 - 2030 (USD Million)
      4.3.3.1.4 liquid
      4.3.3.1.5 liquid market, 2018 - 2030 (USD Million)
    4.3.3.2 Biotech
      4.3.3.2.1 Biotech market, 2018 - 2030 (USD Million)
  4.3.4 Drug
    4.3.4.1 Innovative
      4.3.4.1.1 Innovative market, 2018 - 2030 (USD Million)
    4.3.4.2 Generics
      4.3.4.2.1 Generics market, 2018 - 2030 (USD Million)
  4.3.5 Manufacturing
    4.3.5.1 Continuous manufacturing
      4.3.5.1.1 Continuous Manufacturing market, 2018 - 2030 (USD Million)
    4.3.5.2 Batch manufacturing
      4.3.5.2.1 Batch Manufacturing market, 2018 - 2030 (USD Million)
4.3 Drug Product
  4.3.1 Oral solid dose
    4.3.1.1 Oral solid dose market, 2018 - 2030 (USD Million)
  4.3.2 Semi-solid dose
    4.3.2.1 Semi-solid dose market, 2018 - 2030 (USD Million)
  4.3.3 Liquid Dose
    4.3.3.1 Liquid Dose market, 2018 - 2030 (USD Million)
  4.3.4 Others
    4.3.4.1 Others market, 2018 - 2030 (USD Million)

CHAPTER 5 JAPAN CDMO MARKET: WORK FLOW SEGMENT ANALYSIS

5.1 Japan CDMO: Market Share Analysis, 2021 & 2030
5.2 Japan CDMO Market: Definition and Scope
5.3 Clinical
  5.3.1 Clinical market, 2018 - 2030 (USD Million)
  5.3.2 Commercial
    5.3.2.1 Commercial market, 2018 - 2030 (USD Million)

CHAPTER 6 JAPAN CDMO MARKET: APPLICATION SEGMENT ANALYSIS

6.1 Japan CDMO Market: Definition and Scope
6.2 Japan CDMO: Market Share Analysis, 2021 & 2030
6.3 Oncology
  6.3.1 Oncology market, 2018 - 2030 (USD Million)
6.4 Hormonal
  6.4.1 Hormonal market, 2018 - 2030 (USD Million)
6.5 Glaucoma
  6.5.1 Glaucoma market, 2018 - 2030 (USD Million)
6.6 Cardiovascular Disease
  6.6.1 Cardiovascular Disease market, 2018 - 2030 (USD Million)
6.7 Diabetes
  6.7.1 Diabetes market, 2018 - 2030 (USD Million)
6.8 Others
  6.8.1 Others market, 2018 - 2030 (USD Million)

CHAPTER 7 COMPETITIVE LANDSCAPE

7.1 Company Profiles
  7.1.1 CORDENPHARMA INTERNATIONAL
    7.1.1.1 Company overview
    7.1.1.2 Financial performance
    7.1.1.3 service benchmarking
    7.1.1.4 Strategic initiatives
  7.1.2 WuXi AppTec
    7.1.2.1 Company overview
    7.1.2.2 Financial performance
    7.1.2.3 service benchmarking
    7.1.2.4 strategic initiatives
  7.1.3 Cambrex Corporation
    7.1.3.1 Company overview
    7.1.3.2 Financial performance
    7.1.3.3 Service benchmarking
    7.1.3.4 Strategic initiatives
  7.1.4 Recipharm AB
    7.1.4.1 Company overview
    7.1.4.2 Financial performance
    7.1.4.3 Service benchmarking
    7.1.4.4 Strategic initiatives
  7.1.5 Lonza
    7.1.5.1 Company overview
    7.1.5.2 Financial performance
    7.1.5.3 Service BENCHMARKING
    7.1.5.4 Strategic initiatives
  7.1.6 Catalent, Inc.
    7.1.6.1 Company overview
    7.1.6.2 Financial performance
    7.1.6.3 service benchmarking
    7.1.6.4 Strategic initiatives
  7.1.7 Laboratory Corporation of America Holdings
    7.1.7.1 Company overview
    7.1.7.2 Financial performance
    7.1.7.3 Service benchmarking
    7.1.7.4 Strategic initiatives.
  7.1.8 Thermo Fisher Scientific, Inc
    7.1.8.1 Company overview
    7.1.8.2 Financial Overview
    7.1.8.3 Service benchmarking
  7.1.9 Samsung BioLogics
    7.1.9.1 Company overview
    7.1.9.2 Financial Overview
    7.1.9.3 Service benchmarking
  7.1.10 FUJIFILM Corporation (FUJIFILM Diosynth Biotechnologies U.S.A.)
    7.1.10.1 Company overview
    7.1.10.2 Financial Overview
    7.1.10.3 Service benchmarking
    7.1.10.4 Strategic initiatives
  7.1.11 SUMITOMO CHEMICAL COMPANY, LIMITED
    7.1.11.1 Company overview
    7.1.11.2 Financial performance
    7.1.11.3 Service benchmarking
    7.1.11.4 Strategic initiatives
  7.1.12 CMIC HOLDINGS Co., LTD
    7.1.12.1 Company overview
    7.1.12.2 Financial performance
    7.1.12.3 Service BENCHMARKING
    7.1.12.4 Strategic initiatives
  7.1.13 Bushu Pharmaceuticals LTD.
    7.1.13.1 Company overview
    7.1.13.2 Financial performance
    7.1.13.3 Service benchmarking
    7.1.13.4 Strategic initiatives
  7.1.14 NIPRO
    7.1.14.1 Company overview
    7.1.14.2 Financial performance
    7.1.14.3 Service benchmarking
7.2 Company Market Share Analysis (2021)
LIST OF TABLES

Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Japan pharmaceutical market (USD Thousands)
Table 4 Top 10 causes of death in Japan
Table 5 Expansion
Table 6 Partnership and Collaboration
Table 7 Merger and Acquisition
Table 8 Service and Product launch
Table 9 Joint Venture
Table 10 ADC Approvals in Japan
Table 11 Services offered by CordenPharma International is
Table 12 Services offered by WuXi AppTec
Table 13 Services offered by Cambrex Corporation
Table 14 Services offered by Charles River Laboratory
Table 15 Services offered by Lonza
Table 16 Services offered by Catalent, Inc
Table 17 Services offered by Laboratory Corporation of America Holdings
Table 18 Services offered by Patheon
Table 19 Services offered by Samsung BioLogics
Table 20 Services offered by FUJIFILM Diosynth Biotechnologies U.S.A.
Table 21 Services offered by S-RACMO Co., Ltd
Table 22 Services offered by CMIC HOLDINGS Co., LTD.
Table 23 Services offered by Bushu Pharmaceuticals Ltd.
Table 24 Services offered by Nipro Corporation
LIST OF FIGURES

Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 QFD modeling for market share assessment
Fig. 6 Market formulation & validation
Fig. 7 Commodity flow analysis
Fig. 8 Volume price analysis
Fig. 9 CDMO market snapshot (2020)
Fig. 10 CDMO market segmentation
Fig. 11 Parent market outlook
Fig. 12 Related/ancillary market outlook
Fig. 13 Penetration & growth prospect mapping
Fig. 14 Current & future impact)
Fig. 15 Current & future impact)
Fig. 16 Risk associated with outsourcing services
Fig. 17 Porter’s five forces analysis
Fig. 18 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 19 Segment dashboard
Fig. 20 Product movement analysis
Fig. 21 API market, 2018 - 2030 (USD Million)
Fig. 22 Traditional APIs market, 2018 - 2030 (USD Million)
Fig. 23 HP-API market, 2018 - 2030 (USD Million)
Fig. 24 Antibody-drug conjugate market, 2018 - 2030 (USD Million)
Fig. 25 Others market, 2018 - 2030 (USD Million)
Fig. 26 Synthetic market, 2018 - 2030 (USD Million)
Fig. 27 Solid market, 2018 - 2030 (USD Million)
Fig. 28 Liquid market, 2018 - 2030 (USD Million)
Fig. 29 Biosimilar approval (2012 - 2021)
Fig. 30 Biotech market, 2018 - 2030 (USD Million)
Fig. 31 Innovative market, 2018 - 2030 (USD Million)
Fig. 32 Generics market, 2018 - 2030 (USD Million)
Fig. 33 Continuous manufacturing process of tablets
Fig. 34 Continuous manufacturing market, 2018 - 2030 (USD Million)
Fig. 35 Batch manufacturing process
Fig. 36 Batch manufacturing market, 2018 - 2030 (USD Million)
Fig. 37 Oral solid dose market, 2018 - 2030 (USD Million)
Fig. 38 Semi-solid dose market, 2018 - 2030 (USD Million)
Fig. 39 Liquid dose market, 2018 - 2030 (USD Million)
Fig. 40 Others market, 2018 - 2030 (USD Million)
Fig. 41 Japan CDMO market workflow outlook: Segment dashboard
Fig. 42 Japan CDMO market: Workflow movement analysis
Fig. 43 Japan clinical trial
Fig. 44 Clinical market, 2018 - 2030 (USD Million)
Fig. 45 Commercial market, 2018 - 2030 (USD Million)
Fig. 46 Japan CDMO market synthesis outlook: segment dashboard
Fig. 47 Japan CDMO market: synthesis movement analysis
Fig. 48 Oncology market, 2018 - 2030 (USD Million)
Fig. 49 Hormonal market, 2018 - 2030 (USD Million)
Fig. 50 Glaucoma market, 2018 - 2030 (USD Million)
Fig. 51 Cardiovascular disease market, 2018 - 2030 (USD Million)
Fig. 52 Diabetes market, 2018 - 2030 (USD Million)
Fig. 53 Others market, 2018 - 2030 (USD Million)
Fig. 54 Financial Performance of WuXi AppTec
Fig. 55 Financial performance of Recipharm AB
Fig. 56 Financial Performance of Lonza
Fig. 57 Financial performance of Catalent, Inc.
Fig. 58 Financial Performance of Laboratory Corporation of America Holdings
Fig. 59 Financial Performance of Thermo Fisher Scientific Inc.
Fig. 60 Financial Performance of Samsung BioLogics.
Fig. 61 Financial performance of FUJIFILM Holdings Corp
Fig. 62 Financial performance of Sumitomo Chemical Company, Limited
Fig. 63 Financial performance of CMIC HOLDINGS Co., LTD.
Fig. 64 Financial performance of Nirpo Corporation
Fig. 65 Japan Company Market Share Analysis (2021)


More Publications